Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 13G/APassive | 5.36% | 6.85M | Aug 14, 2026 |
| Commodore Capital LP | 13G/APassive | 1.8% | 2.41M | Aug 14, 2026 |
| Commodore Capital Master LP | 13G/APassive | 1.8% | 2.41M | Aug 14, 2026 |
| Robert Egen Atkinson | 13G/APassive | 1.8% | 2.41M | Aug 14, 2026 |
| Michael Kramarz | 13G/APassive | 1.8% | 2.41M | Aug 14, 2026 |
| Deep Track Capital, LP | 13G/APassive | 3.01% | 3.00M | May 15, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 13G/APassive | 3.01% | 3.00M | May 15, 2026 |
| David Kroin | 13G/APassive | 3.01% | 3.00M | May 15, 2026 |
| Avoro Capital Advisors LLC | 13GPassive | 5.08% | 5.00M | Feb 17, 2026 |
| Behzad Aghazadeh | 13GPassive | 5.08% | 5.00M | Feb 17, 2026 |